(Q35747285)

English

Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials

scientific article published on 6 April 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

0 references

Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials (English)

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Jean-Charles Soria

5

object named as

J C Soria

0 references

author name string

T Reiman

1

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

R Lai

2

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

A S Veillard

3

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

E Paris

4

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

R Rosell

6

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

M Taron

7

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

S Graziano

8

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

R Kratzke

9

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

L Seymour

10

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

F A Shepherd

11

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

J P Pignon

12

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

P Sève

13

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

LACE-Bio Group

14

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

publication date

6 April 2011

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

23

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

86-93

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Class III beta-tubulin expression and in vitro resistance to microtubule targeting agents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3276322

12 July 2018

Ixabepilone: targeting betaIII-tubulin expression in taxane-resistant malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3276322

12 July 2018

Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3276322

12 July 2018

Class III beta-tubulin is a component of the mitotic spindle in multiple cell types

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3276322

12 July 2018

Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3276322

12 July 2018

Class III beta-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3276322

12 July 2018

DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3276322

12 July 2018

Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3276322

12 July 2018

Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3276322

12 July 2018

Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3276322

12 July 2018

Class III β‐tubulin in human development and cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3276322

12 July 2018

Antisense oligonucleotides to class III beta-tubulin sensitize drug-resistant cells to Taxol

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3276322

12 July 2018

Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3276322

25 September 2018

Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3276322

25 September 2018

Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3276322

25 September 2018

Expression of excision repair cross-complementation group 1 and class III beta-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3276322

25 September 2018

Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3276322

25 September 2018

Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3276322

25 September 2018

BetaIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3276322

25 September 2018

Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3276322

25 September 2018

Class III -Tubulin Expression and Benefit from Adjuvant Cisplatin/Vinorelbine Chemotherapy in Operable Non-Small Cell Lung Cancer: Analysis of NCIC JBR.10

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3276322

15 November 2018

Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel

1 reference

https://pubmed.ncbi.nlm.nih.gov/21471564

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of class III beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21471564

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment-by-Histology Interaction Analyses in Three Phase III Trials Show Superiority of Pemetrexed in Nonsquamous Non-small Cell Lung Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21471564

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1093/ANNONC/MDR033

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35747285&oldid=1585108008"